'World revenues for epigenetic therapies and technologies will reach $2.73bn in 2015'

20 October 2011. London. UK. A new report by visiongain, a London-based business information company, predicts that world revenues for epigenetic therapies and technologies will reach $2.73bn in 2015.

Strong uptake of epigenetic technologies, including drug discovery and research tools, will drive this growth. This overall market will grow with a CAGR of 16% between 2010 and 2015, according to Epigenetic Therapies and Technologies: World Market Prospects 2011-2021, published in October 2011.

Therapies will remain the largest source of revenue in the epigenetics market. Four products are available; world revenues from these totalled $0.76bn in 2010. Increased uptake of those drugs, as well as the launch of new therapies, will drive growth in this market sector to 2021, visiongain's study found. As of September 2011, there were five histone deacetylase (HDAC) inhibitors in phase II clinical studies and beyond. The launch of cancer diagnostics based on epigenetic biomarkers will also drive overall market growth from 2011 to 2021.

Richard Lang, pharmaceutical industry analyst, said: "Epigenetics is an exciting and fast-growing area of research. In a little over a decade, the field has moved from early research to the development of second-generation therapies. Greater understanding of the biology behind epigenetics in disease will help improve the selectivity of targeted epigenetic therapies over the next 10 years."

In 2010, revenues from the US, Western Europe and Japan dominated the world epigenetic therapies and technologies market, visiongain's study found. The US accounted for around two thirds of therapy revenues in that year. That dominance will continue as new therapies and diagnostic technologies are launched in those markets first. By 2015, the US will account for over half of the world epigenetics market. Many research institutions are in the US and Western Europe; along with emerging biotechnology companies, they will provide the greatest demand for epigenetic research technologies.

Visiongain forecasts that the overall epigenetic therapies and technologies market will grow strongly to 2021. Increased governmental support and further investment from industry will help move early research into clinical testing and beyond. Further efforts in epigenetic research will identify more epigenetic biomarkers in diseases, broadening the scope for epigenetic therapies and other products. This new study adds to visiongain's wide range of analytical reports for healthcare and other industries.

To view sample pages please visit http://www.visiongain.com/Report/701/Epigenetic-Therapies-and-Technologies-World-Market-Prospects-2011-2021

To request an exec summary please email Sara Peerun
Email: sara.peerun@visiongainglobal.com
Tel +44 207 336 6100

ENDS

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Telecoms, Energy, Pharmaceutical, Defence, Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.

Visiongain Ltd
230 City Road
London
EC1V 2QY
United Kingdom

This release was published on openPR.